OUTLOOK THERAPEUTICS INC Cash Flow Conversion Efficiency
OUTLOOK THERAPEUTICS INC cash flow conversion efficiency. Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.38 Million) by net assets ($-32.19 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of OUTLOOK THERAPEUTICS INC (2014–2025)
Cash flow conversion efficiency of OUTLOOK THERAPEUTICS INC from 2014 to 2025. This chart illustrates how OUTLOOK THERAPEUTICS INC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest OUTLOOK THERAPEUTICS INC stock price today for real-time trading data and today's change.
OUTLOOK THERAPEUTICS INC Cash Flow Conversion Ratio Explained
OUTLOOK THERAPEUTICS INC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
OUTLOOK THERAPEUTICS INC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their cash flow conversion efficiency. Also see market value of OUTLOOK THERAPEUTICS INC for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thirdeye Systems Ltd
TA:THES
|
-0.948x |
|
Samhwa Crown
KO:004450
|
0.011x |
|
Nephros Inc
NASDAQ:NEPH
|
-0.156x |
|
IFirma SA
WAR:IFI
|
0.126x |
|
JT Corporation
KQ:089790
|
0.039x |
|
B. Gaon Holdings Ltd
TA:GAON
|
0.023x |
|
Total Soft Bank Ltd
KQ:045340
|
0.094x |
|
BYC Co Ltd
KO:001465
|
0.020x |
Annual Cash Flow Conversion Efficiency for OUTLOOK THERAPEUTICS INC (2014–2025)
The table below shows the annual cash flow conversion efficiency of OUTLOOK THERAPEUTICS INC from 2014 to 2025. Review free cash flow generation of OUTLOOK THERAPEUTICS INC to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $-32.19 Trillion | $-51.83 Trillion | 1.610x | +71.05% |
| 2024-09-30 | $-73.08 Million | $-68.79 Million | 0.941x | -68.37% |
| 2023-09-30 | $-14.44 Million | $-42.97 Million | 2.976x | +145.88% |
| 2022-09-30 | $8.74 Million | $-56.67 Million | -6.487x | +44.91% |
| 2021-09-30 | $4.61 Million | $-54.25 Million | -11.776x | -4.69% |
| 2020-09-30 | $2.83 Million | $-31.79 Million | -11.249x | -475.20% |
| 2019-09-30 | $-10.77 Million | $-32.29 Million | 2.998x | +88.84% |
| 2018-09-30 | $-20.81 Million | $-33.04 Million | 1.588x | +214.62% |
| 2017-09-30 | $-30.73 Million | $-15.51 Million | 0.505x | -94.23% |
| 2016-09-30 | $-5.20 Million | $-45.48 Million | 8.746x | +649.60% |
| 2015-09-30 | $-23.55 Million | $-27.48 Million | 1.167x | +386.24% |
| 2014-09-30 | $-29.26 Million | $-7.02 Million | 0.240x | -- |
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more